TCR2 Therapeutics to Present New Data from its TRuC™ T Cell Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

CAMBRIDGE, Mass., Oct. 31, 2017 /PRNewswire/ -- TCR² Therapeutics Inc. announced today that new preclinical data from two of its TRuC™ programs will be highlighted at the Society for Immunotherapy of Cancer (SITC) 32^nd Annual Meeting to be held November 8-12, 2017 in National Harbor, Maryland. This includes the lead solid tumor program TC-210 targeting mesothelin that will enter the clinic in 2018.

"We look forward to presenting new data from our TRuC™ programs as they continue to demonstrate robust efficacy, persistence and potential safety benefits in treating solid tumors. We will also share mechanistic data that further validate our approach is truly differentiated from existing CAR or TCR therapies as the first platform to engage the entire T cell receptor complex without HLA restriction," said Robert Hofmeister, PhD, Chief Scientific Officer. "It is an exciting time for TCR² as we advance our TC-210 solid tumor program into the clinic in 2018 and expand our pipeline using TRuC™ technology against several other targets."

The schedule for TCR²'s poster presentations is as follows:

Title: Preclinical Evaluation of Mesothelin-Specific T Cell Receptor Fusion Constructs (TRuC™) Approach Utilizing the Signaling Power of the Complete TCR Complex: A New Opportunity for Solid Tumor Therapy
Poster Number: P171
Date & Time: Friday, November 10, 2017 12:30-2:00pm and 6:30-8:00pm EST
Presenter: Jian Ding, PhD, Senior Scientist, TCR² Therapeutics

Title: TRuC™-T Cells: A Novel Class of Engineered T Cells that Power T Cells Through the Entire T Cell Receptor Complex without MHC Restriction
Poster Number: P193
Date & Time: Friday, November 10, 2017 12:30-2:00pm and 6:30-8:00pm EST
Presenter:  Ekta Patel, PhD, Senior Scientist, TCR² Therapeutics

About TCR² Therapeutics

TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

SOURCE TCR2 Therapeutics

Related Links

http://www.tcr2.com